

# **PSYCHOPATHOLOGICAL CHARACTERISTICS OF EGYPTIAN PATIENTS WITH RHEUMATOLOGIC DISEASES**

**Thesis**

*Submitted in partial fulfilment of the requirements of the M.D.  
degree in Psychiatry*

**By**

**Shirin Mostafa Anwar El-Makawi**

*(M.B.B.Ch., MSC. Neurology and Psychiatry)*

**Supervised by**

**Prof. Dr. Magdi Mohamed Arafa**

*Professor of Psychiatry  
Faculty of Medicine- Cairo University*

**Prof. Dr. Ayman Kamel El Garf**

*Professor of Rheumatology  
Faculty of Medicine- Cairo University*

**Prof. Dr. Samir Mohamed Abou El Magd**

*Professor of Psychiatry  
Faculty of Medicine- Cairo University*

**Prof. Dr. Noha Ahmed Sabry**

*Professor of Psychiatry  
Faculty of Medicine-Cairo University*

**Faculty of Medicine  
Cairo University  
2013**



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا  
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ  
الْحَكِيمُ

صدق الله العظيم  
سورة البقرة الآية (32)



## *Acknowledgements*

*I would like to thank all the people who contributed in some way to the work described in this thesis.*

*Foremost, I would like to express my sincere gratitude to my supervisor **Prof. Dr. Magdy Arafa** for the continuous support of my Ph.D. study and research, for introducing me to the topic, and for his patience, motivation, enthusiasm, and immense knowledge. His guidance helped me in all the time of research and writing of this thesis.*

*I would like to thank **Prof. Dr. Ayman El Garf** for his willingness to supervise this thesis, and for his patience, support and guidance.*

*I would like to express my deep gratitude to my supervisor **Prof. Dr. Samir Abou El Magd**, for his kind support, guidance and help.*

*I would like to express my deep appreciation to my supervisor, **Prof. Dr. Noha Sabry**, for her support, the useful comments, remarks and engagement through the learning process of this thesis.*

*My deep gratitude and appreciation goes to **Dr. Sherine El Mofty**, lecturer of Rheumatology, may she rest in peace, for her sincere, valuable and enthusiastic help and support, for helping in collecting and examining the patients, and for great assistance in the thesis.*

*My sincere thanks also goes to **Dr. Mohamed Mostafa**, lecturer of Public health, who completed the statistics of the thesis, for his patience, kind support and invaluable assistance.*

*I also want to thank **Prof. Dr. Yasser El Miedany**, Professor of Rheumatology, Ain Shams University, for kindly sharing the literature.*

*I would like to thank **Prof. Dr. Lamis El Rai**, head of Psychiatry department, for her continuous support and motivation.*

*At this point I want to thank **Dr. Hoda Bayoumi**, lecturer of Psychiatry, for her assistance and kind support.*

*Furthermore I would also like to acknowledge with much appreciation the crucial role of the staff of rheumatology department in accomplishing the thesis.*

*Special thanks also to the staff members and colleges of psychiatry department for their help and support.*

*Also, I like to thank the participants in the thesis, who have willingly shared their precious time during the process of interviewing.*

*I wish to express my love and gratitude to my family, who have supported me throughout the entire process, and for their endless love, my husband Ayman for his understanding and support throughout the duration of my studies, and my three daughters.*

# *Contents*

	Page
Introduction and Aim of the work	1
Review of literature	
Chapter (1): <ul style="list-style-type: none"><li>• Rheumatologic Diseases</li></ul>	4
Chapter (2): <ul style="list-style-type: none"><li>• Psychiatric Aspects of Rheumatologic Diseases</li></ul>	43
Chapter (3): <ul style="list-style-type: none"><li>• Psychopathologic Dimensions Used in Assessment of Rheumatologic Diseases</li></ul>	70
Subjects and Methods	97
Results	117
Discussion	155
Limitations	190
Conclusions and Summary	191
Recommendations	208
References	211
Arabic Summary	

## **Abstract**

Rheumatologic patients reveal high prevalence of psychiatric disorder, especially depression and anxiety. SLE and RA patients have characteristic features at a dynamic psychopathological level in relation to coping styles, defensive functions and self esteem. SLE and RA patients show characteristic results when relating these psychological variables with clinical variables (disease activity, disease duration, pain).

### **Key words:**

1. Systemic lupus erythematosus
2. Rheumatoid arthritis-coping mechanisms
3. Ego defense mechanisms
4. Self esteem
5. Disease activity

## *List of Abbreviations*

<b>ACR:</b>	<b>American College of Rheumatology</b>
<b>CID:</b>	<b>Coping with illness and disability</b>
<b>CDAI:</b>	<b>Clinical Disease Activity Index</b>
<b>COPD</b>	<b>Chronic Obstructive Pulmonary Disease</b>
<b>CS:</b>	<b>Corticosteroids</b>
<b>CRH:</b>	<b>Corticotropin releasing hormone</b>
<b>DMARD</b>	<b>Disease-modifying anti-rheumatic drug</b>
<b>DAS:</b>	<b>Disease Activity Score</b>
<b>EBV:</b>	<b>Ebstein-Barr Virus</b>
<b>EBNA:</b>	<b>Ebstein-Barr nuclear antigen</b>
<b>GAD:</b>	<b>Generalized Anxiety Disorder</b>
<b>GHQ:</b>	<b>General Health Questionnaire</b>
<b>GM-CSF:</b>	<b>Granulocyte-macrophage stimulating factor</b>
<b>HARS:</b>	<b>Hamilton Anxiety Rating Scale</b>
<b>HDRS:</b>	<b>Hamilton Depression Rating Scale</b>
<b>Hsp:</b>	<b>Heat shock protein</b>
<b>5- HT:</b>	<b>5-Hydroxy-Tryptamine (Serotonin)</b>
<b>5- HTT:</b>	<b>5-hydroxy-Tryptamine      Transporter      (Serotonin transporter)</b>
<b>HRQOL:</b>	<b>Health related quality of life</b>
<b>IL:</b>	<b>Interleukin</b>
<b>LHPA:</b>	<b>Limbic hypothalamic pituitary adrenal axis</b>
<b>MHC:</b>	<b>Major histocompatibility complex</b>
<b>MDD:</b>	<b>Major depressive disorder</b>

<b>NPSLE:</b>	<b>Neuropsychiatric syndromes of systemic lupus erythematosus</b>
<b>PNI:</b>	<b>Psycho – neuro – immunology</b>
<b>PFC:</b>	<b>Prefrontal cortex</b>
<b>RAPID:</b>	<b>Routine Assessment of Patient Index Data arthritis</b>
<b>RA:</b>	<b>Rheumatoid arthritis</b>
<b>RF:</b>	<b>Rheumatoid Factor</b>
<b>SLE:</b>	<b>Systemic lupus erythematosus</b>
<b>SLEDAI:</b>	<b>Systemic Lupus Activity Index</b>
<b>TCR:</b>	<b>T-cell receptor</b>
<b>TGF <math>\beta</math>:</b>	<b>Transforming growth factor <math>\beta</math></b>
<b>TNF:</b>	<b>Tumor necrosis factor</b>
<b>WHO:</b>	<b>World Health Organization</b>
<b>QOL:</b>	<b>Quality of life</b>



## *List of Tables*

Tables		Page
<b>A</b>	<b>Classification Criteria for Rheumatoid Arthritis</b>	<b>10</b>
<b>B</b>	<b>Extra-articular Manifestations of RA</b>	<b>12</b>
<b>C</b>	<b>Classification Criteria for Functional Status in RA</b>	<b>14</b>
<b>D</b>	<b>Classification Criteria for SLE</b>	<b>31</b>
<b>1</b>	<b>Distribution of Sex, Age, Marital Status, Education and Occupation among SLE, RA and Control group</b>	<b>120</b>
<b>2</b>	<b>Type of therapeutic drugs used in SLE and RA patients</b>	<b>121</b>
<b>3</b>	<b>Admission to hospital or attending outpatient clinic</b>	<b>122</b>
<b>4</b>	<b>Systemic Lupus Activity Index (SLEDAI)</b>	<b>123</b>
<b>5</b>	<b>Disease Activity Score (DAS)</b>	<b>123</b>
<b>6</b>	<b>Disease duration in years in SLE and RA groups</b>	<b>123</b>
<b>7</b>	<b>The Multidimensional Health Assessment Questionnaire (Arabic-MDHAQ)</b>	<b>124</b>
<b>8</b>	<b>Psychiatric Disorder Cases and Non Cases in Both Groups: SLE and RA</b>	<b>125</b>
<b>9</b>	<b>Psychiatric Diagnosis Classifications in Both Groups: SLE and RA</b>	<b>127</b>
<b>10</b>	<b>Past history and Family history of Psychiatric disorders in Both Groups: SLE and RA.</b>	<b>128</b>
<b>11</b>	<b>Disease activity in SLE patients and its Relation with psychiatric disorders</b>	<b>129</b>
<b>12</b>	<b>Disease activity in RA patients and its Relation with psychiatric disorders</b>	<b>129</b>
<b>13</b>	<b>HDRS in both Groups: SLE and RA</b>	<b>130</b>
<b>14</b>	<b>HARS in both Groups: SLE and RA</b>	<b>130</b>

<b>15</b>	<b>Self-esteem in SLE, RA and Control</b>	<b>131</b>
<b>16</b>	<b>Defense Styles in SLE, RA and Control group</b>	<b>132</b>
<b>17</b>	<b>Mature Defense Mechanisms in SLE, RA and Control group</b>	<b>134</b>
<b>18</b>	<b>Neurotic Defense Mechanisms in SLE, RA and Control group</b>	<b>136</b>
<b>19</b>	<b>Immature Defense Mechanisms in SLE, RA and Control group</b>	<b>137</b>
<b>20</b>	<b>Coping Mechanisms in SLE, RA and Control group</b>	<b>139</b>
<b>21</b>	<b>Correlation of Clinical variables with Depression, Anxiety, Self-esteem and Helplessness</b>	<b>141</b>
<b>22</b>	<b>Correlation of Clinical variables with Defense Styles among SLE and RA patients</b>	<b>142</b>
<b>23</b>	<b>Correlation of Clinical variables with Mature Defense Mechanisms among SLE and RA patients</b>	<b>143</b>
<b>24</b>	<b>Correlations of Clinical variables with Neurotic Defense Mechanisms among SLE and RA patients</b>	<b>144</b>
<b>25</b>	<b>Correlation of Clinical variables with Immature Defense Mechanisms among SLE and RA patients</b>	<b>145</b>
<b>26</b>	<b>Correlation of Clinical variables with Coping Mechanisms among SLE and RA patients</b>	<b>146</b>
<b>Model 1</b>	<b>To predict Mature Defense Style in SLE and RA patients</b>	<b>148</b>
<b>Model 2</b>	<b>To predict Neurotic Defense Style in SLE and RA patients</b>	<b>148</b>
<b>Model 3</b>	<b>To predict Immature Defense style in SLE and RA patients</b>	<b>149</b>
<b>Model 4</b>	<b>To predict Self esteem in SLE and RA patients</b>	<b>149</b>
<b>Model 5</b>	<b>To predict Adaptive Coping Mechanisms in SLE and RA patients</b>	<b>150</b>
<b>Model 6</b>	<b>To predict Maladaptive Coping Mechanisms in SLE and RA patients</b>	<b>150</b>
<b>Model 7</b>	<b>To predict Psychiatric disorders in SLE and RA patients</b>	<b>151</b>

# *List of Figures*

<b>Figures</b>		<b>Page</b>
<b>A</b>	Percentage of patients with major depression who also suffer from a current anxiety disorders	<b>48</b>
<b>B</b>	Conceptual model of the determinants of health-related outcomes of chronic illness and disability	<b>74</b>
<b>1</b>	Psychiatric Disorders in the Group of Systemic Lupus Ery thematosus	<b>126</b>
<b>2</b>	Psychiatric Disorders in the Group of Rheumatoid	<b>126</b>
<b>3</b>	Self-esteem in SLE, RA and Control group	<b>132</b>
<b>4</b>	Defense Styles in SLE, RA and Control group	<b>133</b>
<b>5</b>	Mature Defense Mechanisms in SLE, RA and Control	<b>135</b>
<b>6</b>	Neurotic Defense Mechanisms in SLE, RA and Control group	<b>136</b>
<b>7</b>	Immature Defense Mechanisms in SLE, RA and Control group	<b>138</b>
<b>8</b>	Coping Mechanisms in SLE, RA and Control group	<b>140</b>



# INTRODUCTION

The WHO (World Health Organization) uses the word “rheumatism” as a heading, under which those diseases are defined that have something to do with the musculoskeletal system and are almost always associated with pain and functional disability (**WHO, 2013**).

Today we have four main groups as well as many subgroups and individual diseases. There are:

The inflammatory rheumatic diseases (e.g. rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis etc.), degenerative joint and vertebrae diseases (very common is osteoarthritis), soft tissue diseases (most known is fibromyalgia) and metabolic diseases associated with rheumatic pain (e.g. osteoporosis) (**Brueckle, 2002**).

For all chronic medical illnesses, an awareness of the interplay between the medical condition and any comorbid psychiatric problems eventually becomes central in the complete management of the patient. The rheumatologic diseases in particular have a colorful history in this regard, rheumatoid arthritis (RA) itself long having been considered one of the pantheon of “holy seven” psychosomatic illnesses (**Moran, 1996**).

The reciprocal interactions among the neural, endocrine, and immune system, called psychoneuroimmunology, is the study of behaviorally associated immunological changes, and immunological



associated behavioral changes and has emerged as a new field of scientific inquiry (**Ader, Cohen & Felten, 1995**).

In recent years there has been a growing trend to explore the psychological features of patients who suffer rheumatologic diseases. Anxiety and depression are the most frequently measured variables (**Moran, 1996**).

Based on **Lazarus and Folkman's, (1994)** stress and coping theory, it is hypothesized that self-esteem and adjustment to disease may contribute to the variability in the impact of pain on psychological health and well-being.

Following their terminology, chronic disease with its typical concomitants such as pain, fatigue and disability is considered to be a permanent stressor that provokes the processes of cognitive appraisal and coping. The association between stress and coping is influenced by psychological resources. One of these resources residing within the self is self-esteem (**Pearlin & Schooler, 1978 and (Sommerfield & McCrae, 2000)**).

Much research has been done on patients suffering from different rheumatologic disease on a descriptive level.

Research concerning deeper psychodynamic dimensions such as defensive styles, coping, and self-esteem for a better understanding of patients with rheumatologic diseases is needed.



## **AIM OF THE WORK**

This study is done to evaluate possible dynamic psychopathological features that may characterize rheumatologic patients.

### **Hypothesis:**

Patients with rheumatologic diseases (SLE and RA) have characteristic features at a dynamic psychopathological level in relation to coping styles, defensive functions, and self esteem.

### **Research Questions**

- 1) Do rheumatologic patients have characteristic features at dynamic levels as regard coping styles, defensive functions, and self esteem compared to healthy controls ?
- 2) Could there be a characteristic significant difference as regard these dimensions among patients with different types of rheumatologic diseases ?



# **RHEUMATOLOGIC DISEASES**

## **History:**

The term rheuma is first encountered in the portion of the Hippocratic corpus titled on the locations in the human body written in the fourth century BC (**Pasero & Marsen, 2004**).

It belongs to the humoral theory of diseases and literally meant ‘flowing’ (**Copeman, 1964**).

With rheumatology, it can be truly said that its origin goes back to antiquity as far back as the ancient Greeks, Indians and Egyptians who suffered, described and named many syndromes (**Paul, 2006**).

Rheumatology developed as a well-recognized speciality in the early half of 20th century. The term rheumatologist was coined in 1940 by two American Physicians, Bernard Comroe (1906–1945) and Joseph Lee Hollander (1910–2000) (**Malavya, 2003**).

The rapid strides in rheumatology during the last 50 years heavily depend on the progress in immunology, molecular biology and genetics which has lead to the development of newer immunological tests for accurate diagnosis of these complex, confusing and some times overlapping spectrum of connective tissue diseases (**Paul, 2006**).